

Early Experience with the GORE® VIAFORT Venous Stent

Andrew Holden, MBChB, FRANZCR
Auckland Hospital
Auckland, New Zealand

VEITH Symposium, November 22nd, 2024





Disclosures

Andrew Holden, MBChB, FRANZCR:

Medical Advisory Board Member for Medtronic, Gore, Philips, Boston Scientific

Clinical Investigator for Bard-BD, Boston Scientific, Cagent Medical, Cook Medical, Eferomol, Endologix, Endospin, Gore Medical, Intact Vascular, Medtronic, Nectero, Philips, Reflow Medical, Shape Memory, Shockwave Medical, Terumo


No other disclosures




GORE® VIAFORT Venous Stent Design

VIAFORT Vascular Stent utilizes ePTFE technology in conjunction with a single wire, sinusoidal-wound nitinol frame

Diameter (mm)	Stent Length (mm)			
	50	75	100	150
10	x	x	x	x
12	x	x	x	x
14	x	x	x	x
16	x	x	x	x
18	x	x	x	x
20	x	x	x	x
24	x	x	x	x
28	x	x	x	x




CAUTION - Investigational device, exclusively for clinical investigation. Limited to United States use in investigational use. The safety and effectiveness of the GORE VIAFORT Venous Stent has not been established. This device may become available to the general public upon completion of IDE at this time. The safety information contained in this presentation is for use based on other approved devices, it does not include and/or alter relevant notices.




GORE® VIAFORT Venous Stent Design

- Self expanding nitinol wire stent
- Fluoropolymer lattice designed for conformability and to allow cross luminal blood flow
- Radiopaque (RO) markers at each device end to facilitate fluoroscopic visualization




CAUTION - Investigational device, exclusively for clinical investigation. Limited to United States use in investigational use. The safety and effectiveness of the GORE VIAFORT Venous Stent has not been established. This device may become available to the general public upon completion of IDE at this time. The safety information contained in this presentation is for use based on other approved devices, it does not include and/or alter relevant notices.




GORE® VIAFORT Venous Stent Design

Delivery system

10 Fr-14 Fr	Device profile varies from 10 Fr to 14 Fr, depending on the configuration.
Radiopaque tip	Delivery system includes a radiopaque tip for visibility of the leading end of the catheter.
120 cm	Catheter working length is 120 cm.



CAUTION - Investigational device, exclusively for clinical investigation. Limited to United States use in investigational use. The safety and effectiveness of the GORE VIAFORT Venous Stent has not been established. This device may become available to the general public upon completion of IDE at this time. The safety information contained in this presentation is for use based on other approved devices, it does not include and/or alter relevant notices.



GORE® VIAFORT IDE Trial Design

Two separate studies: Indication for use in the IVC is being sought under the FDA Breakthrough Designation program

Both studies are prospective, non-randomized, multicenter, single-arm with 5-year follow-up

VNS 21-05 - "IVC Study"


Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction w or w/out Combined Iliofemoral Obstruction

111 Patients
US, AU/NZ, EU
US enrollment completed


VNS 21-07 "Iliofemoral Study"

Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Iliofemoral Venous Obstruction

165 Patients
US Only
Study underway



CAUTION - Investigational device, exclusively for clinical investigation. Limited to United States use in investigational use. The safety and effectiveness of the GORE VIAFORT Venous Stent has not been established. This device may become available to the general public upon completion of IDE at this time. The safety information contained in this presentation is for use based on other approved devices, it does not include and/or alter relevant notices.



GORE® VIAFORT First in Human Case

Patient History:

- 51 Year old male – BMI 26
- Sub-massive PE and DVT 2008 - IVC filter inserted, never removed
- Bilateral leg swelling 2019 – caval and iliac vein thrombosis partially treated with thrombectomy/thrombolysis
- Subsequent resolution of thrombus with anticoagulation but **caval stenosis** noted associated with filter with **strut penetration**

GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Patient History:

- PTS symptoms since 2019
- Significant right leg swelling primary factor preventing normal use
- Venous claudication – pain, specially with exercise
- Right leg VCSS score 2 on 0-3 scale, CEAP C3 (edema)

Partially Occluded IVC Filter
Catheter Used to Inject Contrast

GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Procedural Details:

IVC Filter Removal

- **Per protocol** all subjects with an IVC filter present within the target stent area, must have **IVC filter removal**
- IVC filter initial attempts at retrieval with snare unsuccessful
- Filter dislodged from IVC stenosis with steady, moderate force
- Top of filter would not enter 16Fr sheath
- After some manipulation the filter was removed using brachial forceps
- The room was happy!

GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Procedural Details:

Confirmed Landing Zones and Stent Sizing

- Stent sized using IVC distal to stenosis
- IVC immediately adjacent to renals (proximal to stenosis) significantly larger
- 24mm diameter x 75mm length VIAFORT device chosen
- Indicated vessel range 18-22mm
- Stenosis pre-dilated using a 20mm Atlas balloon

GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Procedural Details:

Confirmed Landing Zones and Stent Sizing

- Stent sized using IVC distal to stenosis
- IVC immediately adjacent to renals (proximal to stenosis) significantly larger
- 24mm diameter x 75mm length VIAFORT device chosen
- **Indicated vessel range 18-22mm**
- Stenosis pre-dilated using a 20mm Atlas balloon

Device Diameter (mm)	Recommended Vessel Diameter (mm)	Introducer Sheath Size (Fr) ¹	Recommended Balloon Diameter for Device Touch-Up (mm)
10	7-9	10	10
12	9-11	11	12
14	11-13	11	14
16	13-15	11	16
18	15-17	12	18
20	17-19	12	20
24	18-22	14	24
28	22-26	14	28

GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Procedural Details:

Stent Deployment

- Accuracy was good and stent landed "beautifully"
- Post-dilation performed with 20mm Atlas balloon to ~6atm


GORE® is investigational device, exclusively for clinical investigation. Limited to United States for investigational use. The safety and effectiveness of the GORE® VIAFORT™ Vascular Stent has not been established. This device may cause injury to the patient and device is contraindicated to GORE at this time. The safety information contained in the Instructions for Use is based on clinical approved devices, it does not include and/or other relevant devices.

VEITH TRIPLEX

GORE® VIAFORT First in Human Case

Post-Stent Deployment

- Lumen widely patent with a circular cross-section (optimal laminar flow)
- Patient discharged the following day with immediate resolution of swelling
 - rVCSW swelling score of 0 out of 3 (down from 2)



GORE® VIAFORT Venous Stent has not been evaluated. The device may cause risks to the patient and should be compared to GORE® at this time. The safety information contained in the Instructions for Use is based on similar approved devices, in vivo testing and/or other relevant sources.

VEITH BY SPYRISK

GORE® VIAFORT First in Human Case

Follow Up:

30-day

- Within his 30d window this patient did not experience any of the primary composite endpoints
- He remains free from death, PE, vascular injury, or major bleeding

12-month

- Within his 12m window this patient did not experience any of the primary composite endpoints
- He remains free from loss of primary patency or stent embolization. This was confirmed with DUS

Long-Term Follow-Up

- This patient is now 24 months post-stent implantation
- He has experienced no serious adverse or adverse events related to the device or procedure
- His last follow-up was on day 706

GORE® VIAFORT Venous Stent has not been evaluated. The device may cause risks to the patient and should be compared to GORE® at this time. The safety information contained in the Instructions for Use is based on similar approved devices, in vivo testing and/or other relevant sources.

VEITH BY SPYRISK

GORE® VIAFORT First in Human Case

6 Month CT:




GORE® VIAFORT Venous Stent has not been evaluated. The device may cause risks to the patient and should be compared to GORE® at this time. The safety information contained in the Instructions for Use is based on similar approved devices, in vivo testing and/or other relevant sources.

VEITH BY SPYRISK

GORE® VIAFORT First in Human Case

12 Month DUS:



GORE® VIAFORT Venous Stent has not been evaluated. The device may cause risks to the patient and should be compared to GORE® at this time. The safety information contained in the Instructions for Use is based on similar approved devices, in vivo testing and/or other relevant sources.

VEITH BY SPYRISK

Early Experience with GORE® VIAFORT Venous Stent

- Only venous stent specifically designed for iliac veins and IVC
- Unique design provides high radial resistive force with excellent conformability
- Early clinical experience very positive
- "IVC Study" has completed enrolment in the US
- "Ilio-femoral Study" (US only) still enrolling


GORE® VIAFORT Venous Stent has not been evaluated. The device may cause risks to the patient and should be compared to GORE® at this time. The safety information contained in the Instructions for Use is based on similar approved devices, in vivo testing and/or other relevant sources.

VEITH BY SPYRISK

Early Experience with the GORE® VIAFORT Venous Stent

Andrew Holden, MBChB, FRANZCR
Auckland Hospital
Auckland, New Zealand

VEITH Symposium, November 22nd, 2024



VEITH BY SPYRISK